Back to List View Graph View

Human serum albumin

Human serum albumin (HSA) is the principal albumin-associated protein considered in the supplied biomedical literature.

Where the papers sit

12 papers from the last 6 months study human serum albumin directly · updated from PubMed 10 Nov 2026

Those 12 are all about one subject.

  • Albumin-Based Biomedicine

    Albumin serves as a carrier, half-life extender, biomaterial, and therapeutic adjunct across drug delivery, radiotracers, clotting factors, hydrogels, and stroke care. Structural stability, chemical modification, and albumin binding recur as determinants of biodistribution, circulation time, and tissue transport. Applications include Ga(III)-NOTA dendrimers, FAP inhibitors, PSMA/GRPR radioligands, and engineered albumin variants. The set is broad and application-driven, without a single convergent clinical or mechanistic direction.

    12 papers

NEW DIRECTION

Human serum albumin becomes a tunable drug-release biomaterial rather than a soluble binding or half-life-extending protein

The human serum albumin-derived hydrogel study uses HSA as the material forming the delivery network, not merely as a soluble binding partner or pharmacokinetic modifier. Reduction-induced partial unfolding drives intermolecular assembly, while cation valency controls gelation, mechanical properties, network density, and doxorubicin release. This assigns HSA a new structural role as a controllable hydrogel scaffold whose architecture directly governs tissue-level drug transport 42314886Jun.

Papers

The 12 papers from the last 6 months that study human serum albumin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Albumin-Based Biomedicine (12)
  1. Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles. Molecular pharmaceutics · 2 Nov 2026 PMID 42969721
  2. Structural conservation and expanded functionality of hyper-stable human serum albumin variants. Protein science : a publication of the Protein Society · 28 Oct 2026 PMID 42948893
  3. Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European stroke journal · 5 Oct 2026 PMID 42831671
  4. Structure-biodistribution relationships of chemically and physically modified albumin: a systematic approach to organ-specific drug delivery. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777828
  5. Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein. Molecular pharmaceutics · 7 Sept 2026 PMID 42704121
  6. Impact of a protein addition on the microstructure and rheological properties of silica hydrogels. Soft matter · 1 Sept 2026 PMID 42676005
  7. Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics. International journal of pharmaceutics · 18 Jul 2026 PMID 42471168
  8. Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
  9. Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood advances · 2 Jul 2026 PMID 42392182
  10. Ion valency-driven control of network architecture and tissue-level drug transport in protein-derived hydrogels. International journal of biological macromolecules · 18 Jun 2026 PMID 42314886
  11. Centrifugal microfluidics for rapid target analyte quantification in airborne bioaerosols. Lab on a chip · 18 Jun 2026 PMID 42312931
  12. Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798

By study type

Clinical trials (1)
  1. Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European stroke journal · 5 Oct 2026 PMID 42831671
Human data, design not indexed (5)
  1. Experimental and Computational Characterization of Human Serum Albumin Recognition by Ga(III)-NOTA Dendrimer Nanomicelles with Distinct PET Biodistribution Profiles. Molecular pharmaceutics · 2 Nov 2026 PMID 42969721
  2. Complexation of teicoplanin and sulfobutylether-β-cyclodextrin: experimental and theoretical insights into the potential relevance of their molecular interaction to teicoplanin pharmacokinetics. International journal of pharmaceutics · 18 Jul 2026 PMID 42471168
  3. Ion valency-driven control of network architecture and tissue-level drug transport in protein-derived hydrogels. International journal of biological macromolecules · 18 Jun 2026 PMID 42314886
  4. Centrifugal microfluidics for rapid target analyte quantification in airborne bioaerosols. Lab on a chip · 18 Jun 2026 PMID 42312931
  5. Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
Preclinical: animal, cell and lab studies (6)
  1. Structural conservation and expanded functionality of hyper-stable human serum albumin variants. Protein science : a publication of the Protein Society · 28 Oct 2026 PMID 42948893
  2. Structure-biodistribution relationships of chemically and physically modified albumin: a systematic approach to organ-specific drug delivery. Journal of controlled release : official journal of the Controlled Release Society · 23 Sept 2026 PMID 42777828
  3. Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein. Molecular pharmaceutics · 7 Sept 2026 PMID 42704121
  4. Impact of a protein addition on the microstructure and rheological properties of silica hydrogels. Soft matter · 1 Sept 2026 PMID 42676005
  5. Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin Binding. Molecular pharmaceutics · 14 Jul 2026 PMID 42447187
  6. Increased gene therapy efficacy through the use of extended half-life clotting factors. Blood advances · 2 Jul 2026 PMID 42392182